Financial Performance - Revenue for the year ended December 31, 2025, was RMB 47,404 thousand, a decrease of 48.3% from RMB 91,885 thousand in 2024[2] - Gross profit for 2025 was RMB 4,264 thousand, with a gross margin of 9.0%, compared to RMB 6,485 thousand and a gross margin of 7.1% in 2024[3] - The net loss for the year was RMB 36,016 thousand, slightly increasing from RMB 36,005 thousand in 2024[4] - Basic and diluted loss per share for 2025 was RMB 0.13, compared to RMB 0.05 in 2024[4] - The group reported a total loss before tax of RMB 35,963,000 for the year ended December 31, 2025, compared to a loss of RMB 35,958,000 in 2024[22] - The pre-tax loss for 2025 was RMB 43,663,000, compared to RMB 81,503,000 in 2024, indicating a significant reduction in losses[26] - The net loss for the reporting period was RMB 36.0 million, reflecting the factors mentioned above[63] Assets and Liabilities - Total assets as of December 31, 2025, were RMB 146,686 thousand, an increase from RMB 137,470 thousand in 2024[5] - Total liabilities decreased to RMB 87,023 thousand in 2025 from RMB 95,077 thousand in 2024[6] - Cash and cash equivalents increased significantly to RMB 27,074 thousand in 2025 from RMB 2,299 thousand in 2024[5] - Inventory decreased to RMB 17,477 thousand in 2025 from RMB 30,713 thousand in 2024[5] - Trade receivables also decreased to RMB 6,227 thousand in 2025 from RMB 24,645 thousand in 2024[5] - The group’s liabilities totaled RMB (87,023,000) as of December 31, 2025, with segment liabilities of RMB (36,048,000) for kitchenware and RMB (578,000) for health-related products[24] - The company's net current assets as of December 31, 2025, were RMB 42.3 million, an increase from RMB 29.3 million as of December 31, 2024[77] Revenue Breakdown - Revenue from kitchenware products in 2025 was RMB 34,507,000, down from RMB 46,821,000 in 2024, representing a decline of 26%[17] - Revenue from health-related products dropped significantly from RMB 45,064,000 in 2024 to RMB 12,897,000 in 2025, a decrease of 71%[17] - Revenue from health-related products accounted for 27.2% of total revenue, amounting to RMB 12.9 million, down from 49.1% or RMB 45.1 million in the previous year[43] - Direct sales from consignment stores decreased by 23.6% to RMB 11.0 million, primarily due to reduced consumer spending amid economic challenges[48] - Sales revenue from corporate clients dropped by 83.3% to RMB 0.1 million, attributed to a decline in orders from Chinese property developers[49] - Direct sales revenue from the television platform decreased by 71.4% to RMB 1.0 million, primarily due to reduced consumer spending[50] - Online platform sales revenue fell by 30.4% to RMB 5.5 million, attributed to poor economic conditions leading to decreased consumer expenditure[51] - Revenue from physical sales locations dropped by 54.4% to RMB 29.8 million, mainly due to adjustments and restructuring of health-related product offerings[52] Expenses and Costs - The group incurred a cost of goods sold of RMB 43,663,000 in 2025, which included inventory write-downs of RMB 6,231,000[26] - Selling and distribution expenses rose by 8.6% to RMB 18.9 million, mainly due to increased promotional and advertising costs[56] - Administrative expenses increased by 6.2% to RMB 15.4 million, primarily due to higher share issuance costs[57] - Research and development expenses decreased by 1.7% to RMB 5.8 million, attributed to cost control measures[58] - Financial costs decreased by 26.2% to RMB 3.1 million, mainly due to the repayment of loans[60] Share Capital and Rights Issue - The company proposed to increase its authorized share capital from HKD 100 million to HKD 150 million by issuing an additional 200,000,000 shares at a nominal value of HKD 0.25 each[69] - The subscription price for the rights issue was set at HKD 0.25 per share, with the market price on the announcement date being HKD 0.158 per share[69] - A total of 208,370,000 unclaimed rights shares were successfully placed at the subscription price of HKD 0.25 per share, with one subscriber acquiring 100,000,000 shares, making them a major shareholder[73] - The total number of shares issued under the rights issue was 242,837,879 shares, with a total nominal value of approximately HKD 60.7 million[74] - The net proceeds from the rights issue, after deducting related expenses, amounted to approximately HKD 58.9 million, equivalent to a net price of about HKD 0.24 per rights share[74] Corporate Governance and Future Plans - The company established a wholly-owned subsidiary, Shenzhen Can Dong Health Technology Co., Ltd., focusing on health data analysis and intelligent services[40] - Future plans include continued investment in digitalization, artificial intelligence, and biotechnology to enhance service capabilities and competitiveness[41] - The company aims to build a comprehensive healthcare service ecosystem, focusing on medical care, digital health, and health management services[39] - The audit committee reviewed the financial reporting system and confirmed that the consolidated financial statements were prepared in accordance with applicable standards[104] - No significant events requiring adjustments or disclosures in the financial statements were identified after the reporting period[106] Employment and Staff - The company employed 52 staff members as of December 31, 2025, down from 69 employees as of December 31, 2024[87]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 AI Health Technology Limited 智 慧 健 康 科 技 有 限 公 司（「本公司」）董 事 會（「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於 二 零 二 六 年 三 月 三 十 一 日（星 期 二）舉 行，以 批 准（其 中 包 括）刊 發 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 五 年 十 二 月 三 十 一 日 止 年 度 的 經 審 核 年 度 業 績，以 及 考 慮 派 付 末 期 股 息（如 有）。 承董事會命 智慧健康科技有限公司 董事會主席及執行董事 於 本 公 告 日 期，本 公 司 執 行 董 事 為 趙 傑 先 生、季 殘 月 女 士 及 吳 惠 璋 先 生；而 本 公 司 獨 立 非 執 行 董 事 為 沈 書 敬 先 生、林 東 明 先 生 及 張 源 潔 女 士。 趙 傑 ...

致：香港交易及結算所有限公司 公司名稱: 智慧健康科技有限公司 (於開曼群島註冊成立的有限公司) FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條，我們在此確認，就上述所列股份類別而言，截至本月底: | | | --- | --- | | 已符合適用的公眾持股量要求（見下方） | ✔ | | 未符合適用的公眾持股量要求（見下方） | | | 根據《主板上市規則》第13.32B條或第19A.28B條 / 《GEM上市規則》第17.37B條或第25.21B條（視情況而定）所載的有關股份類別的最低公眾持股量要求為： | | | 適用的公眾持股量門檻 初始指定門檻 - 上市股份所屬類別的已發行股份總數(不包括庫存股份)的25% | | | | 額外信息 | 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類 ...

Core Viewpoint - Wisdom Health Technology (01715) is strategically positioning itself to capitalize on the growing health industry driven by demographic changes and increased health awareness, particularly in China [1] Group 1: Company Actions - On February 23, shareholders transferred shares from Huatai Securities to Fangde Securities, with a market value of HKD 8.2903 million, representing 5.16% of the total [1] - The company aims to enhance its existing health-related businesses while focusing on the broader health, digital healthcare, and wellness services sectors [1] Group 2: Industry Trends - The global health industry is experiencing unprecedented growth opportunities due to changes in population structure and rising health consciousness [1] - In China, the aging population and widespread application of digital technologies are expanding the "silver economy" within the health market [1] - The company is aligning its strategies with the national "Healthy China" initiative to strengthen its market position [1] Group 3: Business Strategy - Wisdom Health Technology plans to build a comprehensive health service ecosystem covering prevention, diagnosis, medication, rehabilitation, and nursing [1] - The company expects this segment to contribute significantly to its overall revenue [1]

Core Viewpoint - The health technology company, Wisdom Health Technology (01715), is experiencing significant shareholder activity and is strategically positioning itself to capitalize on the growing health industry driven by demographic changes and increased health awareness [1] Group 1: Shareholder Activity - On February 23, Wisdom Health Technology's shares were transferred from Huatai Securities to Fangde Securities, with a market value of HKD 8.2903 million, representing 5.16% of the total shares [1] Group 2: Industry Trends - The global health industry is witnessing unprecedented growth opportunities due to changes in population structure and rising health consciousness [1] - In China, the aging population and widespread application of digital technology are expanding the "silver economy" within the health market [1] Group 3: Company Strategy - In response to the national "Healthy China" strategy, the company aims to strengthen its existing health-related businesses while focusing on the health, digital medical, and wellness service sectors [1] - The company plans to build a comprehensive health service ecosystem covering prevention, diagnosis, medication, rehabilitation, and nursing, with the goal of increasing revenue contributions from this segment [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 智慧健康科技有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01715 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 150,000,000,000 | HKD | | 0.001 HKD | | 150,000,000 | | 增加 / 減少 (-) | | | 0 | | HKD | | 0 | | 本月底結存 | | 150,000,000,000 | HKD | | 0.001 HKD | | 150,000,000 | 本月底法定/註冊股本總 ...

Core Viewpoint - Wisdom Health Technology (01715) announced the resignation of Mr. Li Wei as an independent non-executive director and a member of the audit committee, effective January 12, 2026, to focus on other business commitments [1] Group 1 - Mr. Li Wei will no longer serve as a member of the audit committee following his resignation [1] - Ms. Zhang Yuanjie has been promoted from non-executive director to independent non-executive director, effective January 12, 2026 [1] - Ms. Zhang Yuanjie has been appointed as a member of the audit committee, effective January 12, 2026 [1]

Core Viewpoint - Wisdom Health Technology (01715.HK) announced the resignation of Li Wei as an independent non-executive director and member of the audit committee, effective January 12, 2026, to focus on other business commitments [1] - Zhang Yuanjie has been promoted from non-executive director to independent non-executive director, effective January 12, 2026, and has been appointed as a member of the audit committee [1] Group 1 - Li Wei's resignation is due to his intention to concentrate on other business responsibilities [1] - Zhang Yuanjie’s transition to independent non-executive director and his new role in the audit committee reflects a change in the board's composition [1] - The changes in the board are effective from January 12, 2026, indicating a planned transition [1]

Group 1 - The company announced that Mr. Li Wei has resigned as an independent non-executive director and a member of the audit committee, effective from January 12, 2026, to focus on other business commitments [1] - Ms. Zhang Yuanjie has been appointed as an independent non-executive director, effective from January 12, 2026, transitioning from her previous role as a non-executive director [1] - Following the resignation and appointment, Mr. Li will no longer serve on the audit committee, while Ms. Zhang will join the audit committee effective from January 12, 2026 [1]

AI Health Technology Limited 智慧健康科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1715） 林東明 張源潔 董事會設立3個 委 員 會。下 表 提 供 各 董 事 會 成 員 在 該 等 委 員 會 中 所 擔 任 的 職 位 資 料。 | | 董事委員會 | 審核委員會 | | 提名委員會 | | 薪酬委員會 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 董 事 | | | | | | | | | | 趙 傑 | | | | | | | 成 | 員 | | 季殘月 | | | | 成 | 員 | | | | | 吳惠璋 | | | | | | | | | | 沈書敬 | | 主 | 席 | 主 | 席 | | 成 | 員 | | 林東明 | | 成 | 員 | 成 | 員 | | 主 | 席 | | 張源潔 | | 成 | 員 | | | | | | 香 港，二 零 二 六 年 一 月 十 二 日 本 公 司 董 事（「董 事」）會（「董事會」）成 員 載 列 如 下。 執行董事 ...